Skip to main content
Skip to footer

Dicerna Pharmaceuticals

Dicerna

Careers at Dicerna
News
Contact
Search for:

Our
Company
- Collaborating
- Grants & Charitable Donations
Our GalXC™ and GalXC-Plus™ Technologies
- Scientific Publications
Pipeline
Patients
Press Releases & Presentations
- Press Releases
- Events & Presentations

News

Share this page:

Our mission

We interfere with disease

We use RNA interference, or RNAi, to create medicines that silence the genes that cause or contribute to disease. Our goal is to provide life-changing therapies to people living with rare and common diseases.

Footer

Careers at Dicerna
News
Contact

©2021 Dicerna Pharmaceuticals, Inc. | Lexington, MA
Last revised Apr. 2021

Our
Company
Our GalXC™ and GalXC-Plus™ Technologies
Pipeline
Patients
Media

Privacy Policy
Cookies Policy
Copyright Info
Terms of Use
Glossary of Key Terms

Our
Company
- Collaborating
- Grants & Charitable Donations
Our GalXC™ and GalXC-Plus™ Technologies
- Scientific Publications
Pipeline
Patients
Press Releases & Presentations
- Press Releases
- Events & Presentations
Careers at Dicerna
Contact

Effective 28 December 2021 Dicerna Pharmaceuticals, Inc. is a wholly owned subsidiary of Novo Nordisk A/S

PRESS RELEASE

CONTINUE TO DICERNA.COM

VISIT NOVONORDISK.COM